Antimicrobials 2019
 
Industry Sessions

We are pleased to announce that the following industry sessions will be taking place during the Meeting.

Please note that breakfast symposia numbers are capped for catering purposes, therefore delegates must register to attend the breakfast symposia online via the registration portal. 
  
Lunchtime symposia are free for any delegates who wish to attend on the day. Please collect your lunchbox from the Meeting catering stations and proceed to the symposium. 


bioMerieux Breakfast Symposium - FULLY BOOKED
Thursday, 21 February 2019
07:00 - 08:45 am

Speakers:

Professor Alex van Belkum

"The role of diagnostics in antimicrobial stewardship: A scientific update"

Professor Alex van Belkum, PhD, is a fellow of the American Academy of Microbiology and is currently the scientific director of microbiology research at the diagnostics company bioMerieux. Throughout his career, he has been primarily involved in research on molecular epidemiology, molecular and culture-based diagnostics and antimicrobial resistance testing in the domain of clinical microbiology. Dr van Belkum formerly worked in The Netherlands at the University of Leiden, and the University of Rotterdam, at which he still holds an honorary professorship in molecular microbiology. He moved to bioMerieux in France seven years ago, where he is a microbiologist in the Data Analytics Unit with a prime interest in next generation sequencing and the use of other data-rich technologies in clinical microbiology. Dr van Belkum is the editor-in-chief of the European Journal of Clinical Microbiology and Infectious Diseases. He is the author of more than 540 PubMed-cited papers; has published five books; and is a co-editor of "Molecular Microbiology: diagnostic principles and practice" published by ASM Press, American Society of Microbiology, Washington.

Associate Professor James Branley

"The role of diagnostics in antimicrobial stewardship: Early clinical experience using BioFire FilmArray in an Australian Setting"

A/Prof James Branley is an infectious diseases physician and clinical microbiologist at Nepean Hospital in Western Sydney. He is head of the Infectious Diseases and Microbiology department and previously headed the Division of Medicine as well as serving on the board of Nepean Blue Mountains Local Health District. He is deputy director of Pathology for NSW Health Pathology, at Nepean Hospital. Since 2000, Dr Branley has been a reservist with the Australian Defence Forse (Air Force Specialist Reserve, posted as a pathologist with 1 EHS), deploying to East Timor, Aceh as well as participating in exercises in Australia and Indonesia. He has experience with deployable laboratories and frozen blood. He has recently completed a PhD with the University of Sydney, researching clinical psittacosis. 
 

MSD Lunch Symposium
Thursday, 21 February 2019
12:00 - 13:30 pm

CMV+: What to do with your transplant patient?
 
Speakers: 

Prof. Monica Slavin (Chair)

Opening
 
Dr Michelle Yong
 
"Burden of CMV Infection and Disease in Allo-HSCT Setting"
 
Prof Bill Rawlinson
 
"Mechanism of Action of Anti-CMV Molecules"
 
Dr Emily Blyth
 
"Letermovir - Study evidence of a newly approved terminase inhibitor" 
 
Q&A
 


BD Breakfast Symposium - FULLY BOOKED
Friday, 22 February 2019
07:00 - 08:45 am

From the basement to the corner office: Increasing the influence of the microbiology laboratory in antimicrobial stewardship

Speakers:

Dr Michael Addidle, MBChB, MRCP, FRCPath & DTM&H

"The influence of diagnostic stewardship on antimicrobial stewardship"

Dr Michael Addidle is a UK-trained Clinical Microbiologist who holds consultant posts in both diagnostic and public health laboratories in New Zealand. Michael has a keen interest in the emerging field of diagnostic stewardship, and the development of strong relationships between the microbiology laboratory staff and ward clinicians. Michael currently works at Pathlab Tauranga, New Zealand.

Dr Patrick Murray, PhD

"The role of the laboratory in accelerating patient outcomes"

Dr Patrick R Murray received his Ph.D. degree in Microbiology at UCLA, postgraduate training in Clinical Microbiology at the Mayo Clinic in Rochester MN, and was director of the Clinical Microbiology Laboratories at Barnes Hospital and Professor of Medicine and Pathology at Washington University from 1976 to 1999. In 1999, he joined the faculty of the University of Maryland School of Medicine and in 2001 he accepted the position of Senior Scientist and Chief of Microbiology at the National Institutes of Health. In July 2001, he retired from the NIH and accepted his current position at BD Diagnostics as Vice President, Worldwide Scientific Affairs. He has authored more than 275 research articles and 20 books and has been the recipient of numerous awards and recognitions globally. 

Caitlin Asjes

"Money talks - making the economic case for antimicrobial stewardship"

Caitlin Asjes is BD's Public Policy Director for Greater Asia. In this role, Caitlin supports key initiatives where BD's business goals are aligned to government priorities to increase patient access and address unmet health needs. With a background in health economics, Caitlin has worked across government, business and civil society to support public health programs.


Cepheid Lunch Symposium
Friday, 22 February 2019
12:00 - 13:30 pm

Exploding Myths about GeneXpert: Fun Facts and Fiction

Fred C. Tenover, PhD, D(ABMM), F(AAM), F(IDSA)

Doctor Tenover is Vice President of Scientific Affairs at Cepheid, Consulting Professor of Pathology at Stanford University School of Medicine, Adjunct Professor of Epidemiology in the Rollins School of Public Health at Emory University, and Consulting Professor of Biology at the University of Dayton. He joined the Centers for Disease Control and Prevention in Atlanta in 1990 and served for 18 years as Associate Director for Laboratory Science in the Division of Healthcare Quality Promotion and then as Director of the Office of Antimicrobial Resistance for CDC. He joined Cepheid in California in 2008 where he focused his research studies on carbapenem resistance and the epidemiology of Staphylococcus aureus and Clostridiodes difficile. He is a Diplomate of the American Board of Medical Microbiology and Fellow of both the American Academy of Microbiology and the Infectious Disease Society of America. He has authored over 350 peer-reviewed journal articles and has written or edited 11 books.
 


Abbott Breakfast Symposium - FULLY BOOKED
Saturday, 23 February 2019
07:00 - 08:45 am


From the lab to the patient: Navigating local and international testing pathways for C. difficile infection

Clostridium difficile has recently come to the forefront again with the release of new European and US guidelines that emphasise the importance of the multi-step algorithm approach to prevent over-diagnosis. The symposium will outline the changing epidemiology of C. difficile disease and developing antimicrobial resistance. We will compare international guidelines with current Australian testing practices and provide an overview of a decentralised testing approach by a large pathology network. With Professor Tom Riley, Professor Tony Korman, and Doctor Jacqueline Harper as speakers, the morning is set to be entertaining and informative.

Speakers:

Professor Thomas V Riley BAppSc (Curtin), MAppEpid (ANU), PhD (UWA), FASM, FRCPath, FAAM, FFSc (RCPA)

Tom Riley is currently a Professorial Research Fellow at Edith Cowan University and Professor of Public Health at Murdoch University, both in Perth. He maintains his appointment with PathWest Laboratory Medicine. Tom is a fellow of the Royal College of Pathologists, the Australian Society for Microbiology, the American Academy of Microbiology and the Faculty of Science of the Royal College of Pathologists of Australasia and has published nearly 400 book chapters and refereed journal articles. He has a longstanding interest in healthcare related infections, particularly the diagnosis, pathogenesis and epidemiology of Clostridium difficile infection (CDI), and started working on CDI in animals over 20 years ago. The main focus of his research currently is CDI and One Health. 

Professor Tony Korman MBBS (Hons) (Monash), FRACP, FRCPA, MASM

Tony Korman is the Director of Infectious DIseases and Director of Microbiology at Monash Health, Victoria's largest health service, Infection theme leader, Centre for Inflammatory Diseases, and Associate Professor, Department of Medicine, School of Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University. 

Doctor Jacqueline Harper BSc (Hons), PhD (UQ), FASM, DipBus (AIM)

Jacqueline Harper has a PhD in Medical Microbiology from The University of Queensland and is a Fellow of the Australian Society for Microbiology. She is a Principal Chief Scientist in Microbiology for Pathology Queensland, which is a network of 35 laboratories providing diagnostic services for all  public hospitals throughout the state. She manages the Microbiology Laboratory at the Central Laboratory in Brisbane and oversees Microbiology operations in all Pathology Queensland laboratories. 


Australian Commission on Safety and Quality in Health Care (ACSQHC) Lunch Symposium
Saturday, 23 February 2019
11:30 am - 13:00 pm

Australian Passive AMR Surveillance (APAS): Learnings from long term trends in MROs 2006-2017 and implications for clinical care

Professor John Turnidge AO will lead the session, which will include an overview of long term trends for some significant resistances in Australia, including: methicillin resistance in Staphylococcus aureus, fluoroquinolone non-susceptibility in Escherichia coli, and vancomycin non-susceptibility in Enterococcus faecium. The focus of the discussion will be implications for clinical care, and the audience will be invited to suggest priorities for future analyses of APAS data. 


Thermo Fisher Lunch Symposium
Saturday, 23 February 2019
11:30 am - 13:00 pm

In an Era of Rapid Results, Why Broth Microdilution and the MIC Still Reign

The MIC remains both an incredibly valuable tool for dosing antimicrobials and a potential source for laboratory induced medical errors. With some reports suggesting considerable variation in the MIC based on laboratory methods, standardised testing is essential for accurate dosing. This session will explore why BMD has remained unmatched in providing accurate MIC results, even as novel methods are being developed.
 
Speaker: 
 
Dr Nathan Ledeboer 
 
In this lunch session, Thermo Fisher representatives will also provide an update on the Thermo Fisher Scientific Sensititre system.